267 related articles for article (PubMed ID: 25497972)
21. [Microbiological findings in patients with recurrent vulvovaginal candidiasis in the Hradec Králové Faculty Hospital 1995-2002].
Buchta V; Spacek J
Ceska Gynekol; 2004 Jan; 69(1):7-14. PubMed ID: 15112380
[TBL] [Abstract][Full Text] [Related]
22. Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics.
Naeimi B; Mirhendi H; Khamisipour G; Sadeghzadeh F; Ahmadi B
J Med Microbiol; 2018 Nov; 67(11):1601-1607. PubMed ID: 30248002
[TBL] [Abstract][Full Text] [Related]
23. Different expression levels of
Bonfim-Mendonça PS; Tobaldini-Valério FK; Capoci IR; Faria DR; Sakita KM; Arita GS; Negri M; Kioshima ÉS; Svidzinski TI
Future Microbiol; 2021 Mar; 16():211-219. PubMed ID: 33595345
[No Abstract] [Full Text] [Related]
24. Can the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar?
Novikova N; Rodrigues A; Mårdh PA
Infect Dis Obstet Gynecol; 2002; 10(2):89-92. PubMed ID: 12530485
[TBL] [Abstract][Full Text] [Related]
25. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance.
Li X; Chen S; Lyu X; Tian J
Med Mycol; 2022 Nov; 60(11):. PubMed ID: 36328948
[TBL] [Abstract][Full Text] [Related]
26. Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis.
Yano J; Noverr MC; Fidel PL
mBio; 2017 Mar; 8(2):. PubMed ID: 28292981
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species.
Guzel AB; Ilkit M; Akar T; Burgut R; Demir SC
Med Mycol; 2011 Jan; 49(1):16-25. PubMed ID: 20608776
[TBL] [Abstract][Full Text] [Related]
28. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
Fan S; Liu X; Wu C; Xu L; Li J
Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition of Candida albicans by vaginal cells from naïve mice.
Steele C; Ozenci H; Luo W; Scott M; Fidel PL
Med Mycol; 1999 Aug; 37(4):251-9. PubMed ID: 10421860
[TBL] [Abstract][Full Text] [Related]
30. Differential interaction of the two related fungal species Candida albicans and Candida dubliniensis with human neutrophils.
Svobodová E; Staib P; Losse J; Hennicke F; Barz D; Józsi M
J Immunol; 2012 Sep; 189(5):2502-11. PubMed ID: 22851712
[TBL] [Abstract][Full Text] [Related]
31. Comparative Analysis of the Capacity of the
Willems HME; Lowes DJ; Barker KS; Palmer GE; Peters BM
Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249743
[TBL] [Abstract][Full Text] [Related]
32. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil.
Lopes Consolaro ME; Aline Albertoni T; Shizue Yoshida C; Mazucheli J; Peralta RM; Estivalet Svidzinski TI
Rev Iberoam Micol; 2004 Dec; 21(4):202-5. PubMed ID: 15709802
[TBL] [Abstract][Full Text] [Related]
33. Methods Related to the Immunopathogenesis of Vulvovaginal Candidiasis and Associated Neutrophil Anergy.
Yano J; Fidel PL
Methods Mol Biol; 2022; 2542():193-218. PubMed ID: 36008666
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Collins LM; Moore R; Sobel JD
J Low Genit Tract Dis; 2020 Jan; 24(1):48-52. PubMed ID: 31860575
[TBL] [Abstract][Full Text] [Related]
35. Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity.
Akimoto-Gunther L; Bonfim-Mendonça Pde S; Takahachi G; Irie MM; Miyamoto S; Consolaro ME; Svidzinsk TI
PLoS One; 2016; 11(7):e0158870. PubMed ID: 27415762
[TBL] [Abstract][Full Text] [Related]
36. Vaginal microbiological flora and sexually transmitted diseases in women with recurrent or current vulvovaginal candidiasis.
Zdolsek B; Hellberg D; Fröman G; Nilsson S; Mårdh PA
Infection; 1995; 23(2):81-4. PubMed ID: 7622268
[TBL] [Abstract][Full Text] [Related]
37. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis.
Raska M; Belakova J; Horynova M; Krupka M; Novotny J; Sebestova M; Weigl E
Med Mycol; 2008 Aug; 46(5):411-20. PubMed ID: 18608941
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Garvey EP; Hoekstra WJ; Schotzinger RJ; Sobel JD; Lilly EA; Fidel PL
Antimicrob Agents Chemother; 2015 Sep; 59(9):5567-73. PubMed ID: 26124165
[TBL] [Abstract][Full Text] [Related]
39. Candida vaginitis during contraceptive use: the influence of methods, antifungal susceptibility and virulence patterns.
Güzel AB; Küçükgöz-Güleç U; Aydin M; Gümral R; Kalkanci A; Ilkit M
J Obstet Gynaecol; 2013 Nov; 33(8):850-6. PubMed ID: 24219728
[TBL] [Abstract][Full Text] [Related]
40. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen.
Fidel PL; Ginsburg KA; Cutright JL; Wolf NA; Leaman D; Dunlap K; Sobel JD
J Infect Dis; 1997 Sep; 176(3):728-39. PubMed ID: 9291322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
